Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB: TRUFF) reported its Q1 2026 financial results, showing a revenue of $1.301M, down from $1.559M in Q1 2025, with a gross profit of $0.447M. The company maintained a strong cash position of $11.454M, despite higher cash utilization for debenture payment ($653K) and Bitcoin ETF purchase ($210K).
Notable achievements include entry into the U.S. retail market through Albertsons, launch of Health Canada-approved Functional Mushroom Gummies, and a pilot program with Real Canadian Superstore. The company announced a $2M Bitcoin strategy and partnerships with Irvine Labs and Arizona State University for psychedelic research. SR Wholesale remained cash-positive with steady sales growth in Dutch SmartShops.
Red Light Holland (OTCQB: TRUFF), a company focused on functional mushrooms and psilocybin truffles, has provided an update on its Bitcoin investment strategy. The company has acquired 10,600 shares of iShares Bitcoin ETF (IBIT) at an average cost of C$44.60 per share as part of its C$2 million Bitcoin allocation plan.
The company is also establishing a corporate account with a major exchange to implement algorithmic trading strategies through Arch Public Inc., following the recommendation of Lead Cryptocurrency Advisor Scott Melker. This initiative aims to strengthen the company's treasury while aligning with its vision of innovation and decentralization.
Red Light Holland (OTCQB: TRUFF), a producer of functional mushrooms and magic truffles, has welcomed the DEA's historic decision to forward a psilocybin rescheduling petition to HHS for review. This marks the first-ever advancement of a petition to potentially reclassify psilocybin from Schedule I to Schedule II.
The company, through CEO Todd Shapiro, expressed optimism about the review, highlighting psilocybin's potential therapeutic benefits for anxiety, depression, and PTSD. The rescheduling could enable compassionate use programs, enhanced research development, and future FDA approvals.
Additionally, Red Light Holland reported successful validation of its natural psilocybin truffles through third-party testing at Irvine Labs, confirming their compatibility with potential medical grade manufacturing applications.
Red Light Holland (OTCQB:TRUFF) has received initial third-party testing results from Irvine Labs, validating the psilocybin potency and process compatibility of its naturally occurring psilocybin products for potential medical grade manufacturing applications.
Following the first global psilocybin shipment from the Netherlands to Irvine Labs' FDA-compliant and DEA-registered facility in California in July 2025, the company is now advancing the development of proprietary dehydration and packaging processes to extend shelf life while maintaining product integrity. The partnership aims to create standardized psilocybin products for emerging therapeutic markets, government-funded pilot programs, and clinical trials in the United States.
Red Light Holland (OTCQB: TRUFF), a company focused on functional mushrooms and legal psilocybin truffles, announced that CEO Todd Shapiro will participate in the Blockchain Futurist Conference in Miami on November 5-6, 2025.
Shapiro will conduct a fireside chat and host a panel discussion exploring the intersection of blockchain technology, cryptocurrency, and the psychedelics industry. The discussions will focus on how blockchain principles can support psychedelic deregulation and enhance personal sovereignty in health and financial decisions.
The company recently announced a strategic move to allocate up to C$2 million to Bitcoin and related assets, appointing Scott Melker as Lead Cryptocurrency Advisor. A live Q&A session is scheduled for July 30, 2025, at 11:00 AM EST to discuss year-end results and the Bitcoin Balance Sheet Strategy.
Red Light Holland (OTCQB: TRUFF) reported its FY2025 audited results, showing strategic growth and improved operational efficiency. The company achieved revenue of $4.944M (up 4.05% YoY) while significantly reducing its EBITDA loss by 49.04% to $3.354M.
Key achievements include successful retail partnerships with Costco Canada and Albertsons, a groundbreaking psilocybin shipment to Irvine Labs in California, and the appointment of Dr. Robin Carhart-Harris as Scientific Advisor. The company maintains a strong cash position of $12.838M and announced a $2M investment in Bitcoin assets as part of its balance sheet strategy.
Despite challenges including debanking issues and slower Dutch tourism, the company demonstrated resilience through diversified revenue streams and strategic innovations in psilocybin R&D.
Red Light Holland (OTCQB: TRUFF), a company focused on functional mushrooms, home grow kits, and psilocybin truffles, has scheduled the release of its 2025 audited year-end results for Tuesday, July 29th, 2025, before market open.
The company will host a live Q&A session on Wednesday, July 30th, 2025, at 11:00 AM EST, featuring CEO Todd Shapiro and CFO Keith Li. The financial results will be accessible through SEDAR PLUS and the company's website.
Red Light Holland (OTCQB: TRUFF), a company focused on functional mushrooms and psilocybin truffles, has selected Arch Public Inc. as its partner for executing Bitcoin purchases, following advice from Lead Cryptocurrency Advisor Scott Melker. This decision aligns with the company's recently announced Bitcoin balance sheet strategy from July 15, 2025.
The company is implementing a C$2 million allocation to Bitcoin and related assets, with strategic investments of up to C$250,000 per tranche. Red Light Holland has already invested C$210,000 in a Bitcoin ETF on June 23, 2025. Arch Public's algorithmic trading platform will help optimize Bitcoin entry points and enhance treasury diversification through automated, emotion-free trading strategies.
Red Light Holland (OTCQB: TRUFF), a producer of functional mushrooms and psilocybin truffles, has announced a significant Bitcoin Balance Sheet Strategy with a planned allocation of up to C$2 million to Bitcoin and related assets. The company has already invested an initial C$210,000 in a Bitcoin ETF on June 23, 2025.
The company has appointed cryptocurrency expert Scott Melker as Senior Advisor and Crypto Czar, effective July 14, 2025. Melker, known as "The Wolf of All Streets" with over 1 million followers on X, will receive 3,333,333 restricted stock units vesting over 12 months. This strategic move follows the company's experience of being debanked by a Tier 1 bank, leading them to embrace Bitcoin as a store of value.
Red Light Holland (OTCQB: TRUFF) has achieved a significant milestone by completing the first-ever global shipment of naturally occurring psilocybin from its Netherlands facility to Irvine Labs, an FDA-compliant and DEA-registered facility in California. The shipment was made possible through a USA Controlled Substances import permit.
The partnership aims to develop commercialized and standardized psilocybin products for emerging markets and government-funded programs within the United States. Irvine Labs will conduct potency testing and implement advanced shelf life extension protocols on the received materials, leveraging their proprietary preservation technology to maintain product integrity throughout the supply chain.
The company's 2025 DEA quota allocation allows for scaling of R&D processes, with larger shipments being planned for future development.